Famotidine, 40 mg 30 pcs

Gastroduodenitis, Heartburn, Sour belching, Gastric and duodenal ulcer, Subscapular pain, Reflux esophagitis, GastritisFamotidine is recommended for inpatients who are unable to take the drug orally. Parenteral administration of famotidine may be used until oral therapy becomes feasible.

– Duodenal ulcer disease;

– peptic ulcer without malignization (good clinical effect in response to famotidine administration does not allow to exclude the presence of ulcer malignization);

– gastroesophageal reflux disease;

– other conditions accompanied by hypersecretion of gastric juice (e.g., Zollinger-Ellison syndrome);

– prevention of Mendelson syndrome (aspiration of acidic gastric contents) during general anesthesia.

Active ingredient

Composition

How to take, the dosage

The drug is for intravenous administration only!

The initial dose for intravenous administration should not exceed 20 mg twice a day (every 12 hours).

The contents of the vial should be dissolved in 5-10 ml of 0.9% sodium chloride solution (solvent ampoule) and then slowly injected (for at least 2 minutes). When infusing the drug, the solution should be administered for 15-30 minutes.

The solutions should be prepared immediately before administration. Only clear, colorless solutions can be used.

Hypersecretory conditions, gastric and duodenal ulcer in the acute stage:

– slowly bolus, over 2 minutes, 20 mg 2 times a day;

– drip, over 15-30 minutes, 20 mg 2 times a day.

Reflux esophagitis

– 20 mg 2 times daily intravenously slowly.

Zollinger-Ellison syndrome

The initial dose is 20 mg intravenously every 6 hours. If necessary, the dose of the drug is increased depending on the volume of acid production and the clinical condition of the patient.

To prevent aspiration of acidic gastric contents during general anesthesia

20 mg in the morning on the day of surgery or at least 2 hours before surgery.

Renal failure

Children

The safety and efficacy of the drug in children have not been fully established.

Elderly (over 65 years of age)

Dose adjustment depending on age is not necessary.

Interaction

Compatible with 0.9% sodium chloride solution, 5% dextrose solution, 4.2% sodium bicarbonate solution.

It increases absorption of amoxicillin and clavulanic acid.

Antacids and sucralfate slow down absorption of famotidine after oral administration.

Reduces absorption of itraconazole and ketoconazole.

Medications that depress bone marrow increase the risk of neutropenia.

Special Instructions

The presence of gastric malignancy should be excluded before initiating therapy or, if this is not possible, before switching to oral therapy.

Because cross-allergy has been described in the case of H2-histamine receptor blockers, the use of famotidine in patients with a history of hypersensitivity to other H2-histamine receptor blockers requires caution.

Patients should exercise caution when performing activities that require rapid psychomotor reactions (including driving motor vehicles.including driving vehicles and operating machinery) because dizziness and increased fatigue may occur during treatment.

Contraindications

– Hypersensitivity to famotidine or other components of the drug;

– pregnancy and breast-feeding period;

– age under 18 years.

Hepatic and/or renal failure, liver cirrhosis with encephalopathy (in anamnesis), immunodeficiency states.

A history of allergy to other H2-histamine blockers (cross-sensitivity may be present).

Side effects

The incidence of adverse effects after using the drug is classified according to the WHO recommendations: rare (≥1/10000 and < 1/1000), very rare (< 1/10000), frequency unknown (it is not possible to determine the incidence according to available data).

Gastrointestinal tract: rarely – diarrhea, constipation; very rarely – feeling of abdominal discomfort, nausea, vomiting, dry mouth, anorexia, various taste disorders.

Hepatic and biliary tract disorders: very rare – cholestatic jaundice.

The central nervous system: rarely – headache, very rare – dizziness, convulsive epileptiform seizures.

Psychiatric disorders: very rare – depression, hallucinations, agitation, anxiety, confusion, insomnia; somnolence.

Musculoskeletal system: very rare – arthralgia, myalgia. muscle cramps.

The blood and lymphatic system: very rare – agranulocytosis, leukopenia, pancytopenia, thrombocytopenia.

Skin and subcutaneous tissue disorders: very rarely – acne, alopecia, dry skin, toxic epidermal necrolysis.

Hearing and vestibular system disorders: frequency is unknown – tinnitus.

Gender and mammary gland disorders: very rare – gynecomastia (reversible when treatment is discontinued), decreased libido, impotence.

The immune system: very rarely – anaphylaxis, urticaria, skin rash, hyperemia of sclerae and skin, angioedema, edema of periorbital areas of the eyes, face.

Cardiovascular system disorders: very rarely – arrhythmia, atrioventricular block, palpitation.

Respiratory system, thorax and mediastinum: very rarely – bronchospasm.

General disorders and disorders at the site of administration: very rare – increased fatigue, asthenia, fever.

Laboratory and instrumental data: very rarely – increased activity of “liver” enzymes.

Overdose

In patients with pathological hypersecretion syndrome, doses of up to 800 mg per day have been prescribed for a period of more than one year, with no serious adverse events.

Similarities